Janux Therapeutics, Inc. Common Stock Stock Prediction
AI-powered sentiment analysis and prediction trends for JANX, updated each market day.
JANX AI Sentiment
AI predicts Janux Therapeutics, Inc. Common Stock stock is likely to decrease over the next 10 market days.
Prediction date: April 10, 2026
Subscribers see precise scores, buy/sell targets, and full analytics.
About Janux Therapeutics, Inc. Common Stock
Janux Therapeutics Inc is a clinical-stage biopharmaceutical company developing tumor-activated immunotherapies for cancer. The proprietary technology of the company has enabled the development of distinct bispecific platforms: Tumor Activated T Cell Engagers (TRACTr), Tumor Activated Immunomodulators (TRACIr), and Adaptive Immune Response Modulator (ARM) platforms. The TRACTr platform produces T cell engagers (TCEs) with a tumor antigen-binding domain and a CD3 T cell binding domain, while the TRACIr platform produces bispecifics with a tumor antigen-binding domain and a costimulatory CD28 binding domain.
Sector
Exchange
Market Cap
$883,883,961
Cap Tier
Employees
109
Headquarters
SAN DIEGO, CA
Listed Since
June 11, 2021
Website
JANX Sentiment Trend — Last 30 Predictions
Sentiment zones: Bullish · Neutral · Bearish
JANX Volatility
Janux Therapeutics, Inc. Common Stock has shown high price volatility over the last 5 trading days. High volatility means larger price swings — this can present both opportunity and risk for traders.
